These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33206282)

  • 41. A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin
    Wu X; Wynne C; Xu C; Gan Y; Wang C; Thomas BE; Yu JC; Li S; Zhang L
    BioDrugs; 2019 Jun; 33(3):335-342. PubMed ID: 31016568
    [TBL] [Abstract][Full Text] [Related]  

  • 42. GP2013: A Rituximab Biosimilar.
    Blair HA
    BioDrugs; 2017 Oct; 31(5):465-468. PubMed ID: 28921160
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
    Kim WS; Coiffier B; Kwon HC; Kim S
    Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
    Serna-Gallegos TR; La-Fargue CJ; Tewari KS
    Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FDA Approves First Biosimilar to Treat Cancer.
    Cancer Discov; 2017 Nov; 7(11):1206. PubMed ID: 28982661
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PF-06410293: An Adalimumab Biosimilar.
    Lee A; Shirley M
    BioDrugs; 2020 Oct; 34(5):695-698. PubMed ID: 32949384
    [TBL] [Abstract][Full Text] [Related]  

  • 47. LA-EP2006: A Pegfilgrastim Biosimilar.
    Hoy SM
    BioDrugs; 2019 Apr; 33(2):229-232. PubMed ID: 30887256
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A review of CT-P13: an infliximab biosimilar.
    McKeage K
    BioDrugs; 2014 Jun; 28(3):313-21. PubMed ID: 24723086
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men.
    Singh I; Patel R; Patel A; Jose V
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):193-202. PubMed ID: 32627073
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Etanercept biosimilar SB-4.
    Pelechas E; Drosos AA
    Expert Opin Biol Ther; 2019 Mar; 19(3):173-179. PubMed ID: 30616405
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
    von Pawel J; Spigel DR; Ervin T; Losonczy G; Barlesi F; Juhász E; Anderson M; McCall B; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Reck M
    Oncologist; 2018 Jun; 23(6):654-e58. PubMed ID: 29438092
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics, Tolerability, Safety, and Immunogenicity of LY01008 and Bevacizumab (Avastin®) in Healthy Chinese Subjects.
    Xie L; Zhu Y; Liang Z; Zhao Y; Zhou S; Chen J; Zhang H; Ding S; Wang L; Shao F
    Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):309-317. PubMed ID: 35112328
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SB5: An Adalimumab Biosimilar.
    Frampton JE
    BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
    [TBL] [Abstract][Full Text] [Related]  

  • 54. AVT02: An Adalimumab Biosimilar.
    Kang C
    Clin Drug Investig; 2022 Oct; 42(10):875-878. PubMed ID: 36181655
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?
    Tu CL; Wang YL; Hu TM; Hsu LF
    BioDrugs; 2019 Aug; 33(4):437-446. PubMed ID: 31111423
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review.
    Chingcuanco F; Segal JB; Kim SC; Alexander GC
    Ann Intern Med; 2016 Oct; 165(8):565-574. PubMed ID: 27479870
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar.
    Hoy SM
    BioDrugs; 2019 Feb; 33(1):117-120. PubMed ID: 30701419
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin
    Wynne C; Schwabe C; Batra SS; Lopez-Lazaro L; Kankanwadi S
    Br J Clin Pharmacol; 2018 Oct; 84(10):2352-2364. PubMed ID: 29943831
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer.
    Socinski MA; Waller CF; Idris T; Bondarenko I; Luft A; Beckmann K; Vishweswaramurthy A; Loganathan S; Donnelly C; Hummel MA; Shapiro R; Woods M; Rao A; Nayak VG; Ranganna G; Barve A
    Ther Adv Med Oncol; 2021; 13():17588359211045845. PubMed ID: 34819997
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evolution of the EU Biosimilar Framework: Past and Future.
    Wolff-Holz E; Tiitso K; Vleminckx C; Weise M
    BioDrugs; 2019 Dec; 33(6):621-634. PubMed ID: 31541400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.